D842V

D842V is a mutation in the BRCA1 gene, which is associated with an increased risk of developing breast and ovarian cancer. The mutation is a substitution of the amino acid aspartic acid (D) at position 842 with valine (V). BRCA1 is a tumor suppressor gene that plays a crucial role in DNA repair and cell cycle control. Mutations in BRCA1 can lead to a loss of its function, resulting in genomic instability and increased cancer risk.

The D842V mutation is a truncating mutation, which means it prematurely stops the production of the BRCA1 protein. This truncation can lead to a loss of BRCA1's DNA repair capabilities, allowing for the accumulation of mutations in the genome that can drive cancer development.

The D842V mutation is relatively rare, accounting for less than 1% of all BRCA1 mutations. It is most commonly found in individuals of Ashkenazi Jewish descent, where it is estimated to occur in about 1 in 400 individuals. However, it can also be found in other populations at a lower frequency.

Individuals with the D842V mutation have an increased risk of developing breast cancer, with an estimated lifetime risk of about 60-70%. The risk of developing ovarian cancer is also increased, with an estimated lifetime risk of about 15-20%. The risk of other cancers, such as pancreatic and prostate cancer, may also be increased.

Genetic counseling and testing are important for individuals with a family history of breast or ovarian cancer, as well as for those with the D842V mutation. Early detection and management of cancer, as well as lifestyle modifications such as regular exercise and a healthy diet, can help reduce the risk of cancer development and improve outcomes.